Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neoadjuvant Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing

Trial Profile

Neoadjuvant Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2019

At a glance

  • Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Nivolumab (Primary)
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Oct 2018 Status changed from not yet recruiting to recruiting.
    • 28 Aug 2018 According to Caris Life Sciences media release, HCRN GU16-257 is open to patient enrollment at The Tisch Cancer Institute at Mount Sinai in New York City, NY.
    • 28 Aug 2018 According to Caris Life Sciences media release, company has been selected by the Hoosier Cancer Research Network and the study's sponsor investigator, Dr. Matthew Galsky, to perform genomic tumor profiling for a new Phase II bladder cancer clinical trial, HCRN GU16-257.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top